This website uses cookies

This website uses cookies to ensure you get the best experience. By using our website, you agree to our Privacy Policy

International In-house Counsel Journal logoInternational In-house Counsel Journal logo

Blocking Effect of the Blocking Act?

Abstract

The Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch Waxman Act 1984, was enacted in 1984 to balance the privileges offered to brand name pharmaceutical companies, helping them to continue to innovate, with those to the generic pharmaceutical companies, providing incentives to bring low-cost generics early to the market. In 2019, The Lower Health Care Costs Act of 2019, was introduced in The House of Representatives, to improve public health and to end surprise medical bills. Interestingly, one of the provisions of this Bill, BLOCKING Act of 2019, proposes to remove the barrier to an approval of subsequent Abbreviated New Drug Application posed by the 180 days exclusivity of the first filer. The Bill is proposed to reduce the out- of- pocket expenses on health care, a purpose similar to why the Hatch Waxman act was enacted. Does this proposal however, have a flip side, threatening to do exactly opposite of what it proposes to do?

Read Paper

Author

Portrait image of Anagha Tendulkar
Anagha Tendulkar
In-house Patent Counsel, Cipla, India

Anagha Tendulkar, is an In-house counsel at Cipla Limited, India. Her role majorly focusses on activities relating to ANDA litigations and includes pre-litigation, in- litigation and post- litigation strategizing for early product launch. Other activities include portfolio selection, priming on legal and regulatory hurdles, strategic decision making, due diligence for small molecules and biologicals, etc. Professional background She has about 15 years of experience in this field. Prior to joining Cipla Limited, she was an In- house counsel at Panacea Biotech, India. Her role was to manage various IP related activities for the organization, including identifying early market entry opportunities, patent due diligences, design- around strategies, patent drafting and prosecution. Presentations • Speaker- National Seminar organized by PES, Modern College of Pharmacy, India- “Patent Basics and Overview of Generic Drugs in US” • Invited to address on “Patents- an insight” at a symposium, Modern College of Pharmacy, India Publications/ Posters • "Induced Infringement under US Patent Law" Anagha Tendulkar, Patent In- house counsel, Cipla. International In-house Counsel Journal Vol. 15, No. 59, Spring 2022, 1 “Written Description Requirement of Patentability” Anagha Tendulkar, Patent In- house counsel, Cipla. International In-house Counsel Journal Vol. 15, No. 58, Winter 2022, 1 . “Blocking Effect of the Blocking Act?” Anagha Tendulkar, Patent In- house counsel, Cipla. International In-house Counsel Journal Vol. 14, No. 55, Spring 2021, 1 • “Demethylation and Transcriptional activation of genes involved in metastasis of pancreatic cancer by Methyl-CpG-binding domain 2. ” Tendulkar S. , Ou J. -N. , Tendulkar A. , Szyf M. Pharmacological research day (PRD) annual meeting Montreal, CANADA, Jun 2006. • “Demethylation and Transcriptional activation of genes involved in metastasis of pancreatic cancer by Methyl-CpG-binding domain 2. ” Tendulkar S. , Ou J. -N. , Tendulkar A. , Szyf M. AACR, Washington D. C. , Apr 2006. • “Metabolic engineering of Yeast: Yarrowia lipolytica” Tendulkar A. , Bhave S. Chattoo B. B. , International meeting - “Yeast 2003”, IMTECH, Chandigarh, India, Feb 2003. Education • LL. B, University of Mumbai • Registered Patent Agent, India • P. G. Diploma in Patent Management, AIPS, Mumbai • Research Associate, Department of Pharmacology, McGill University, Canada • Research Fellow, MSU, Baroda, India • Post-graduation, University of Mumbai (Microbiology/ Biotechnology) Achievements • Qualified- Joint All- India CSIR-UGC Test, CSIR, New Delhi, India • Qualified- State Eligibility Test, University of Pune, Maharashtra, India • Awarded Certificate of merit, Post-graduation, University of Mumbai

Company

Cipla logo

Cipla

Cipla Limited is an Indian multinational pharmaceutical company, headquartered in Mumbai, India. It primarily develops medicines to treat respiratory, cardiovascular disease, arthritis, diabetes, weight control, depression, and other medical conditions. Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For over 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 100 countries. Its portfolio includes over 1000 products across wide range of therapeutic categories with one quality standard globally. Cipla’s emphasis on access for patients was recognized globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than a dollar a day and thereby treating many millions of patients since 2001.

Related Papers

An Effective, Practical Approach to International Competition Law Compliance
The traditional approach to antitrust or competition law compliance is to start with the parade of horribles that can flow from a violation (jail, fines, damages, bad press), then stress...Read more
Portrait image of Kent Bernard
Kent Bernard
Member, Bar of the Commonwealth of Pennsylvania, U.S.A., Kent Bernard, USA
Different Approaches to Pricing and Reimbursement of Innovative Pharmaceutical Products in Europe
All aspects of the pharmaceutical market are heavily regulated due to the major public health implications related to the use of pharmaceutical products. Pricing and reimbursement of pharmaceutical products is...Read more
Portrait image of Renato Dellamano
Renato Dellamano
President, Value Vector, Italy
Payback Time: Trump and EU’s “Exorbitant” Fines vs US Tech Companies
The election of Donald Trump for a second term of the US Presidency is of considerable concern to the European Union (EU), NATO, and states worldwide in general owing to...Read more
Portrait image of Roy Girasa
Roy Girasa
Professor of Law, Pace University, USA
The Competition (Amendment) Act, 2023 and its Impact on Inter-Corporate Deliberations
The Parliament of India enacted the Competition (Amendment) Act, 2023 (“Amendment Act”), which was initially introduced as a Bill in August 2022, during the Monsoon Session. This legislation, which...Read more
Portrait image of Nupur Nadir
Nupur Nadir
Head - Legal, GEPL, GMR Group, India
Portrait image of Sreyasi Banerjee
Sreyasi Banerjee
Associate Manager - Legal Counsel, GMR Group, India